I-Mab Inks Partnership With Bristol Myers Squibb To Evaluate Givastomig In Combination Study
(RTTNews) - Biotech company I-Mab (IMAB) announced Wednesday that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb (BMY).
The collaboration will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody jointly developed by I-Mab and ABL Bio, with Bristol Myers Squibb's immune checkpoint inhibitor, nivolumab, and chemotherapy (FOLFOX or CAPOX), as a potential first-line treatment for patients with advanced Claudin 18.2-positive gastric and esophageal cancers.
Under the terms of the agreement, the study will be a multi-national Phase 1 study conducted by I-Mab. Bristol Myers Squibb will supply nivolumab.
Nivolumab is an immune checkpoint inhibitor that is designed to block the PD-L1 protein on cancer cells from binding to PD-1, enhancing T-cell function and resulting in improved anti-tumor responses.
Bristol Myers Says Type II Variation Application For Opdivo + Yervoy Granted EMA Validation
Perspective Therapeutics Inks Clinical Trial Collaboration Agreement With Bristol Myers
Bristol-Myers Squibb Guides FY24 Adj. EPS Above Estimates As Q4 Results Top Estimates - Update
Bristol Myers Squibb To Acquire RayzeBio For $62.50/share In All-cash Deal
Bristol Myers Squibb To Acquire Karuna Therapeutics For $330/share Cash
Avidity Biosciences Inks Global Licensing And Research Collaboration Deal With Bristol Myers Squibb
Bristol-Myers Squibb Boosts FY23 Adj. EPS Outlook As Q3 Adj. EPS Tops Estimates
